Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
NCT ID: NCT01766817
Last Updated: 2020-08-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
325 participants
INTERVENTIONAL
2013-01-31
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
NCT04308681
To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
NCT05497284
SB17170 Phase 2 Trial in IPF Patients
NCT06747923
Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
NCT00514683
Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
NCT05130970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: BMS 986020, 600 mg. once daily
BMS-986020, 600 mg tablets, by mouth, once daily, 26 weeks
BMS-986020
Arm 2: BMS-986020, 600 mg twice daily
BMS-986020, 600 mg tablets, by mouth, twice daily, 26 weeks
BMS-986020
Arm 3: Placebo matching with BMS-986020
Placebo, 0 mg tablets, by mouth, twice daily, 26 weeks
Placebo matching with BMS-986020
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986020
Placebo matching with BMS-986020
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have clinical symptoms consistent with IPF.
* Have first received a diagnosis of IPF less than 6 years before randomization. The date of diagnosis is defined as the date of the first available imaging or surgical lung biopsy consistent with IPF/UIP.
* Have a diagnosis of usual interstitial pulmonary fibrosis (UIP) or IPF by HRCT or surgical lung biopsy (SLB).
* Extent of fibrotic changes (honeycombing, reticular changes) greater than the extent of emphysema on HRCT scan.
* Have no features supporting an alternative diagnosis on transbronchial biopsy, BAL, or SLB, if performed.
* Have percent predicted post-bronchodilator FVC between 45% and 90%, inclusive, at screening.
* Have a change in post-bronchodilator FVC (measured in liters) between screening and day 1 that is less than a 10% relative difference, calculated as: the absolute value of 100% \* (screening FVC (L) - day 1 FVC (L)) / screening FVC (L).
* Have carbon monoxide diffusing capacity (DLCO) between 30% and 80% (adjusted for hemoglobin and altitude), inclusive, at screening.
* Have no evidence of improvement in measures of IPF disease severity over the preceding year, in the investigator's opinion.
* Be able to walk 150 meters or more at screening.
* Demonstrate an exertional decrease in oxygen saturation of 2 percentage points or greater at screening (may be performed with supplemental oxygen titrating to keep oxygen saturation levels \>88%).
* Are able to understand and sign a written informed consent form.
* Are able to understand the importance of adherence to study treatment and the study protocol and are willing to comply with all study requirements, including the concomitant medication restrictions, throughout the study.
* Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must use acceptable method(s) of contraception. The individual methods of contraception and duration should be determined in consultation with the investigator. WOCBP must follow instructions for birth control when the half-life of the investigational drug is less than 24 hours, contraception should be continued for a period of 30 days after the last dose of investigational product.
1. Women must have a negative urine pregnancy test within 24 hours prior to the start of investigational product.
2. Women must not be breastfeeding.
3. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men that are sexually active with WOCBP must follow instructions for birth control when the half-life of the investigational drug is less than 24 hours, contraception should be continued for a period of 90 days after the last dose of investigational product.
4. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and azoospermic men do not require contraception.
Exclusion Criteria
1. Has significant clinical worsening of IPF between screening and day 1 (during the screening process), in the opinion of the investigator.
2. Has forced expiratory volume in 1 second (FEV1)/FVC ratio less than 0.8 after administration of bronchodilator at screening.
3. Has bronchodilator response, defined by an absolute increase of 12% or greater and an increase of 200 mL in FEV1 or FVC or both after bronchodilator use compared with the values before bronchodilator use at screening.
Medical History and Concurrent Diseases
1. Has a history of clinically significant environmental exposure known to cause pulmonary fibrosis, including, but not limited to, drugs (such as amiodarone), asbestos, beryllium, radiation, and domestic birds.
2. Has a known explanation for interstitial lung disease, including, but not limited to, radiation, drug toxicity, sarcoidosis, hypersensitivity, pneumonitis, bronchiolitis, obliterans, organizing pneumonia, human immunodeficiency virus (HIV), viral hepatitis, and cancer.
3. Has a clinical diagnosis of any connective tissue disease, including, but not limited to, scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, rheumatoid arthritis, and undifferentiated connective tissue disease.
4. Currently has clinically significant asthma or chronic obstructive pulmonary disease.
5. Has clinical evidence of active infection, including, but not limited to, bronchitis, pneumonia, sinusitis, urinary tract infection, and cellulitis.
6. Has any history of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next 2 years. This does not include minor surgical procedures for localized cancer (e.g., basal cell carcinoma).
7. Has any condition other than IPF that, in the opinion of the investigator, is likely to result in the death of the subject within the next 2 years.
8. Has a history of end-stage liver disease.
9. Has a history of end-stage renal disease requiring dialysis.
10. Has a history of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months, including, but not limited to, the following: i. Unstable angina pectoris or myocardial infarction ii. Congestive heart failure requiring hospitalization iii. Uncontrolled clinically significant arrhythmias
11. Has any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of BMS-986020.
12. Has a history of alcohol or substance abuse in the past 2 years.
13. Has a family or personal history of long QT syndrome and/or Torsades de Pointes (polymorphic ventricular tachycardia).
14. Has used any of the excluded medications per Appendix 1 of the Protocol, which includes, but is not limited to:
* current treatment with pirfenidone or nintedanib
* use of over-the-counter medications and herbal preparations, within 4 weeks before study drug administration except those medications cleared by the BMS medical monitor
* For subjects taking statins, there are restrictions on the maximum allowable doses for statins listed below. If subjects are currently taking statins and their doses are higher than those mentioned below, please reduce the dose to the maximum allowable dose.
Additionally, if subjects are on statins and ready to start dosing, these subjects should limit statin doses by maximal allowable dose or lower for at least 5 days prior to the first BMS-986020 dosing. Shorter durations may be considered in select cases after discussion with the medical monitor.
Maximum allowable dose for statins:
* Simvastatin 20 mg QD
* Pitavastatin 2 mg QD
* Atorvastatin 40 mg QD
* Pravastatin 40 mg QD
* Rosuvastatin 20 mg QD
* Lovastatin 40 mg QD
* Fluvastatin 40 mg QD
* Prednisone is allowed up to a maximum of 15 mg po daily
* Pirfenidone or nintedanib dosing for a maximum of 3 months in the prior 12 months is permitted with a 4 week washout period prior to dosing with BMS-986020.
Physical and Laboratory Test Findings
1. Has any of the following liver-function test criteria above the specified limits: total bilirubin \>1.5 x ULN, excluding subjects with Gilbert's syndrome; aspartate or alanine aminotransferase (AST/SGOT or ALT/SGPT) greater than 3 x ULN; alkaline phosphatase greater than 2.5 x ULN.
2. Has creatinine clearance less than 30 mL/minute, calculated using the Cockcroft-Gault formula.
3. Has ECG result with a QT interval by Fridericia's correction (QTcF) of 500 msec or greater or an uncorrected QT of 500 msec or greater at screening. Note: For subjects with a machine read QT interval of \>500 msec, if their heart rate is \> 100 bpm, the machine read QT interval (either corrected or not) may not be accurate. If the investigator is uncertain about the QT abnormality, it is recommended that ECGs be over-read by a cardiologist. The manually read QT interval by a cardiologist should be used for assessment of eligibility whenever possible.
Allergies and Adverse Drug Reaction Has had prior use of BMS-986020 or has known hypersensitivity to any of the components of study treatment.
1. Is not a suitable candidate for enrollment or is unlikely to comply with the requirements of this study, in the opinion of the investigator.
2. Has smoked cigarettes within 4 weeks or screening or is unwilling to avoid tobacco products throughout the study.
3. Is expected to receive a lung transplant within 1 year from randomization or, for subjects at sites in the United States, is on a lung-transplant waiting list at screening.
4. Prisoners or subjects who are involuntarily incarcerated.
5. Subjects who are compulsorily detained for treatment either of a psychiatric or physical (e.g., infectious disease) illness.
6. Inability to comply with restrictions and prohibited activities/treatments as listed in Section 3.3 of the Protocol.
40 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham - Division of Pulmonary, Allergy & Criticial Care
Birmingham, Alabama, United States
St. Joseph's Hospital and Medical Center - Heart Lung Institute/ Clinical Research
Phoenix, Arizona, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
University of California at San Francisco
San Francisco, California, United States
Stanford University Medical Center
Stanford, California, United States
National Jewish Health
Denver, Colorado, United States
Yale University School of Medicine, Section of Pulmonary & Critical Care
New Haven, Connecticut, United States
Advanced Pulmonary & Sleep Research Institute of Florida
Daytona Beach, Florida, United States
University of Florida
Gainesville, Florida, United States
ILD Research Center
Miami, Florida, United States
Cleveland Clinic Florida- Weston Hospital
Weston, Florida, United States
University of Chicago
Chicago, Illinois, United States
Via Christi Clinic
Wichita, Kansas, United States
University of Kentucky- Center for Clinical and Translational Science
Lexington, Kentucky, United States
University of Louisville
Louisville, Kentucky, United States
Tulane University
New Orleans, Louisiana, United States
Johns Hopkins University
Baltimore, Maryland, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
University of Michigan Health System
Ann Arbor, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Mayo Clinic, Pulmonary Clinical Research Unit
Rochester, Minnesota, United States
CardioPulmonary Research Center
Chesterfield, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Pulmonary & Allergy Associates, PA
Summit, New Jersey, United States
ISA Clinical Research
Forest Hills, New York, United States
Weill Cornell Medical College
New York, New York, United States
Highland Hospital
Rochester, New York, United States
Asheville Pulmonary and Critical Care Associates, P.A.
Asheville, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
University of Cincinnati Pulmonary, Critical Care & Sleep Medicine
Cincinnati, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
The Ohio State University
Columbus, Ohio, United States
The Oregon Clinic
Portland, Oregon, United States
Oregon Health Science University
Portland, Oregon, United States
Temple Lung Center
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center - Simmons Center for Interstitial Lung Disease
Pittsburgh, Pennsylvania, United States
Vanderbilt University
Nashville, Tennessee, United States
University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, United States
Metroplex Pulmonary and Sleep Center
McKinney, Texas, United States
Alamo Clinical Research
San Antonio, Texas, United States
University of Texas Health Science Center at Tyler
Tyler, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Vermont Lung Center
Colchester, Vermont, United States
Inova Fairfax Medical Campus
Falls Church, Virginia, United States
University of Wisconsin Hospital & Clinics
Madison, Wisconsin, United States
Local institution
Westmead, New South Wales, Australia
Local institution
Greenslopes, Queensland, Australia
Local Institution
Adelaide, South Australia, Australia
Local institution
Frankston, Victoria, Australia
Local institution
Nedlands, Western Australia, Australia
Local institution
Viña del Mar, Región de Valparaíso, Chile
Local institution
Quillota, , Chile
Local institution
Santiago, , Chile
Local Institution
Talca, , Chile
Hospital Pablo Tobon Uribe
Medellín, Antioquia, Colombia
Fundacion Neumologica Colombiana
Bogota, Cundinamarca, Colombia
Hospital Universitario San Ignacio
Bogota, Cundinamarca, Colombia
Local Institution
Bogota, Cundinamarca, Colombia
Local Institution
Guadalajara, Jalisco, Mexico
Local Institution
Mexico City, Mexico City, Mexico
Local Institution
Mexico City, Mexico City, Mexico
Local Institution
Monterrey, Nuevo León, Mexico
Local Institution
Monterrey, Nuevo León, Mexico
Local Institution
Monterrey, Nuevo León, Mexico
Local institution
Lima, , Peru
Local Institution
Lima, , Peru
Local institution
Lima, , Peru
Local institution
Lima, , Peru
Local institution
Lima, , Peru
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Decato BE, Leeming DJ, Sand JMB, Fischer A, Du S, Palmer SM, Karsdal M, Luo Y, Minnich A. LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis. Respir Res. 2022 Mar 18;23(1):61. doi: 10.1186/s12931-022-01980-4.
Palmer SM, Snyder L, Todd JL, Soule B, Christian R, Anstrom K, Luo Y, Gagnon R, Rosen G. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest. 2018 Nov;154(5):1061-1069. doi: 10.1016/j.chest.2018.08.1058. Epub 2018 Sep 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM136-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.